Pancreatic Disease Registry

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2013 by Columbia University
Sponsor:
Information provided by (Responsible Party):
Jeanine Genkinger, Columbia University
ClinicalTrials.gov Identifier:
NCT01102556
First received: April 12, 2010
Last updated: September 6, 2013
Last verified: September 2013

April 12, 2010
September 6, 2013
March 2004
March 2014   (final data collection date for primary outcome measure)
Creation of a registry and blood/tissue bank [ Time Frame: 1 year ] [ Designated as safety issue: No ]
The primary aims of this project are to create a registry, and blood and tissue bank for individuals at risk for pancreatic cancer.
Same as current
Complete list of historical versions of study NCT01102556 on ClinicalTrials.gov Archive Site
Improvement in the diagnosis, prevention, detection, and treatment of pancreatic cancer. [ Time Frame: 10 years ] [ Designated as safety issue: No ]
The long-term goals of the study are to advance the knowledge of the etiology and epidemiology of pancreatic cancer. The epidemiological data will be correlated with the biological information and will allow for future investigative studies of pancreatic cancer etiology and tumor biology. It is anticipated and hypothesized that the knowledge derived will lead to improvements in the diagnosis, prevention, detection, and treatment of pancreatic cancer.
Same as current
Not Provided
Not Provided
 
Pancreatic Disease Registry
PREDICT: Pancreatic Disease Cohort. A Registry and Biospecimen Bank To Better Understand Pancreatic Disease.

The specific aims of this project are to create a registry, as well as a biospecimen bank for individuals with pancreatic disease (e.g. pancreatic adenocarcinoma, pancreatitis, intraductal papillary mucinous neoplasm (IPMN) mucinous cystic neoplasm (MCN), and pancreatic intraepithelial neoplasia (PanIN) or have been determined to be at high-riskfor pancreatic cancer. Biospecimen can be defined as blood, urine, tissue, stool, or saliva samples. Therefore, no hypothesis is to be tested. The personal data derived from the registry, correlated with biological information derived from the biospecimens will allow for future investigative studies of pancreatic cancer etiology and tumor biology. The long-term goals of the study are to advance the knowledge of the etiology and epidemiology of pancreatic cancer. It is anticipated that the knowledge derived will ultimately lead to improvements in the diagnosis, prevention, detection,and treatment of pancreatic cancer.

Pancreatic cancer is the fourth leading cause of cancer death in both men and women in the United States. According to the American Cancer Society facts and figures, approximately 43,920 people in the United Sates will be diagnosed with pancreatic cancer in 2012, and it is expected that 37,390 will die from the disease. The dismal prognosis of the disease is clearly depicted by the fact that its incidence approximates its mortality. Pancreatic cancer has a 95% case fatality rate.

The etiology of pancreatic cancer remains elusive and our knowledge of its precursors and natural history is preliminary and incomplete. The uniform fatality of the disease merits priority attention in the search for its cause.

Due to the rapid progression of the disease, early detection and prevention provides the best hope for reducing morbidity and mortality. However, the few screening tests available for early detection and/or prevention of neoplastic lesions are poorly studied and prohibitively impractical in the general population. Further, few pancreatic cancer risk factors are well established or widely accepted. Advanced age, family history, cigarette smoking, diabetes, and some dietary risk factors are established or suspected risk factors.

Due to the high volume of individuals seen at the pancreas center, we plan on enrolling 500+ individuals per year who have either been diagnosed with pancreatic disease or are at high risk for developing pancreatic cancer. All participants enrolled during a clinic/non clinic visit at CUMC will undergo a baseline visit and up to 3 subsequent visits. Additionally, based on the different conditions of pancreatic disease that we are enrolling, not all subjects will participate in all aspects of the program. For example, only individuals with cancer or pre-neoplastic lesions will have tissue collected and banked.

Observational [Patient Registry]
Observational Model: Cohort
Time Perspective: Prospective
1 Year
Retention:   Samples With DNA
Description:
  • Peripheral Blood Specimens: Three tubes of blood will be collected from each study participant. Two tubes will be EDTA-whole blood and one tube will be serum. Each tube will contain ~4-5 ml. The whole blood will be frozen and stored. A portion of the blood will be utilized to extract white blood cells that will be immortalized by EBV infection.
  • Archived Fixed Tissue Samples: Tissue blocks from surgery performed at CUMC or elsewhere, will be requested after obtaining consent for study participation.
  • Fresh Tissue Collection: At the time of surgery for any tumor resection, tumor tissue and adjacent normal tissue will be requested from the Pathology Department. At the time of endoscopy, aspirated fluid or biopsied tissue will be requested. No additional tissue will be resected beyond that required for surgical or endoscopic management. In no circumstance will tissue be obtained solely for the purpose of the study.
Non-Probability Sample

Individuals who have been diagnosed with pancreatic cancer or suspicion of pancreatic cancer, a pre-neoplastic lesion in the pancreas, or who have been identified to be at high-risk for developing pancreatic cancer.

Pancreatic Cancer
Not Provided
Surgery Patients/High-risk Patients
Patients who have undergone surgery for pancreatic cancer or pre-neoplastic lesions of the pancreas will be accrued to the study. In addition, patients who are determined to be at high-risk for pancreatic cancer (with a significant family history) will also be recruited for study enrollment.
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
1000
June 2014
March 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Individuals who have been diagnosed with pancreatic cancer or suspicion of pancreatic cancer, a pre-neoplastic lesion in the pancreas who are 18 years or older
  • Individuals identified to be high risk for developing pancreatic cancer who are 18 years or older based on the following criteria:
  • The modified clinical Bethesda criteria for HNPCC, which are as follows: individuals with 2 HNPCC-associated cancers (colon, endometrial, small bowel, hepatobiliary, pancreatic, genitourinary, or gastric), including synchronous or metachronous lesions; individuals with colon cancer and a first degree relative with an HNPCC-associated tumor and/or colonic adenoma (1 cancer diagnosed at age <45 years and the adenoma diagnosed at age <40 years); individuals with colon or endometrial cancer diagnosed at <50 years; individuals with right-sided colon cancer having an undifferentiated pattern (solid/cribiform) or signet cell histopathology diagnosed at <45 years; or individuals with adenomas diagnosed at <40 years.
  • Those with a personal or family history of other pancreatic cancer associated syndromes including: Peutz-Jeghers syndrome, familial pancreatic cancer syndrome, familial breast cancer syndrome associated with BRCA-2 or BRCA-1, hereditary pancreatitis, familial atypical multiple mole melanoma, and others.
  • Patients in a family with a genetically determined cancer predisposition syndrome.
  • Patients with a personal history of a gastrointestinal malignancy at age <45 years.
  • Individuals at high-risk based on personal or family history, but not related to a known pancreatic cancer syndrome include the following: those with a personal history of pancreatic cancer, or a pre-neoplastic pancreatic lesion; those with a family history of two or more individuals with cancer, at least one of which is reported to be a gastrointestinal malignancy; a history of early onset (<50 years) gastrointestinal cancer in the individual or a family member; a history of multiple primary cancers, at least one of which is a gastrointestinal primary, or a family member of an individual meeting this criterion.

Exclusion Criteria:

  • Inability to obtain informed consent for study enrollment.
  • Under the age of 18 years old.
Both
18 Years to 85 Years
Yes
Contact: Ashley Dikos 212-305-9812 ajd2147@columbia.edu
Contact: Vilma Rosario 212-305-6033 vr2222@columbia.edu
United States
 
NCT01102556
AAAA6154
Yes
Jeanine Genkinger, Columbia University
Columbia University
Not Provided
Principal Investigator: Jeanine Genkinger, PhD Columbia University
Columbia University
September 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP